Viridian Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VRDN research report →
Range $31 – $47
Price Chart
About the company
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED).
- CEO
- Stephen F. Mahoney
- IPO
- 2014
- Employees
- 252
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on VRDN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.40B
- P/E
- -8.12
- Fwd P/E
- 159.74
- PEG
- 0.44
- P/S
- 135.71
- P/B
- 6.14
- EV/EBITDA
- -8.37
- Div Yield
- 0.00%
- Gross Margin
- 92.98%
- Op Margin
- -1781.38%
- Net Margin
- -1724.06%
- ROE
- -69.76%
- ROIC
- -48.85%
Latest fiscal year · YoY change
- Revenue
- $70.85M+23359.9%
- Gross Profit
- $70.85M+23359.9%
- Op Income
- $-363,395,000
- Net Income
- $-342,601,000-26.9%
- EPS
- $-3.32+16.6%
- OCF Growth
- -19.0%
- FCF Growth
- -18.9%
- 52W High
- $34.29
- 52W Low
- $13.18
- 50D MA
- $23.35
- 200D MA
- $21.52
- Beta
- 0.96
- RSI (14)
- 74
- Avg Volume
- 2.13M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Viridian reported a strong first quarter for Lumvoa with $24.7 million in net product revenue, more than 100 patients on therapy, and early payer progress that management says exceeded expectations.· November 4, 2026
- Lumvoa generated $24.7 million in net product revenue in its first quarter on the market, with more than 100 patients on therapy at quarter end.
- Management said the launch exceeded expectations and was driven by strong physician engagement, rapid field execution, and demand rather than stocking.
- Payer progress is advancing: more than 90% of covered lives were represented in post-approval meetings, and 30% of covered lives had a policy in place by the end of September.
- CMS assigned Lumvoa a permanent J-code effective January 1, 2027, which management said supports reimbursement clarity going forward.
- The pipeline remains a major focus, with an elegrobart BLA on track for first quarter 2027 and first-in-human VRDN-008 data expected later this quarter.
Viridian reported Lumvoa net product revenue of $24.7 million in its first quarter on the market. Management said there were more than 100 patients on therapy as of September 30, and those were actual patients who had started treatment and completed at least one infusion. The company ended the quarter with just over $955 million in cash equivalents and marketable securities. No EPS, gross margin, or other companywide profitability metrics were given on the call. Forward-looking commentary included broad Lumvoa coverage targeted within six to nine months from launch, a permanent J-code effective January 1, 2027, an elegrobart BLA submission targeted for the first quarter of 2027, a phase I start for VRDN-292 later this quarter, and first-in-human VRDN-008 data later this quarter.
Steve Mahoney framed the quarter as a strong start to Lumvoa’s launch and repeatedly emphasized that the results were better than expected. His tone was confident but disciplined: he highlighted the launch execution, then pointed to Viridian’s pipeline as the next growth chapter, including elegrobart, VRDN-008, and VRDN-292. He also stressed that the same infrastructure used for Lumvoa should support future launches, suggesting the company views the commercialization playbook as repeatable.
Seth Harmon kept the financial update brief and focused on the balance sheet, saying Viridian ended the quarter with just over $955 million in cash equivalents and marketable securities. He said the company is in a strong financial position to fund and execute current plans through profitability. On revenue recognition and reimbursement mechanics, management said revenue is recognized when received by specialty distributors, and they noted extended payment terms were offered during the J-code transition period to support infusion centers.
Most of the Q&A focused on whether Lumvoa’s early revenue and patient starts represented a one-time bolus or the beginning of sustained uptake. Tony Casciano pushed back on the idea of a bolus, saying TED is an urgent condition and the market does not lend itself to a big catch-up wave, though he repeatedly cautioned that it is still early. Analysts also pressed on the relationship between start forms and treated patients, the apparent dose volume implied by revenue, and whether the company was seeing broad adoption or just a few prescribers. Management said most patients started late in the quarter, there was not much stocking, and adoption is coming from the targeted core prescriber base, with some docs trialing the drug and others switching more aggressively.
The bull case from this call is that Lumvoa appears to be off to a materially faster-than-expected commercial start, with $24.7 million in first-quarter revenue and more than 100 treated patients. Management also sees early payer progress, a permanent J-code, and a focused prescriber base that could support efficient conversion and sustained growth. The pipeline adds another layer of optionality, especially if elegrobart, VRDN-008, and VRDN-292 continue to advance as planned.
The main risk is that this is still very early launch data, and management would not commit to Q4 pacing, share, or the level of repeatability. They also said broad coverage is still incomplete at 30% of covered lives, with the rest dependent on ongoing policy rollout and medical exception processes. Several answers implied that investors should not overread the quarter, since the company said it needs to see whether current demand sustains over subsequent quarters.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 93.9%
- Shares Outstanding
- 113.56M
- Float Shares
- 106.61M
of shares held by institutions
230 13F filers
Buy/sell ratio 2.67. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 17.51M | ▲ 904.40K |
| Blackrock, Inc. | 9.33M | ▲ 777.66K |
| Bellevue Group AG | 6.73M | ▲ 5.76K |
| Paradigm Biocapital Advisors LP | 6.72M | ▲ 3.57M |
| Kynam Capital Management, LP | 6.45M | ▲ 4.11M |
| Price T Rowe Associates Inc | 5.75M | ▲ 2.54M |
| Vanguard Group Inc | 5.61M | ▲ 1.28M |
| Fairmount Funds Management LLC | 5.09M | ▲ 1.18M |
| State Street Corp | 4.88M | ▼ 1.25M |
| Vanguard Capital Management LLC | 4.75M | ▲ 177.63K |
| Deep Track Capital, LP | 3.59M | ▲ 2.20M |
| Venrock Adviser, LLC | 3.26M | ▼ 624.79K |
Held by 318 ETFs
Biggest fund positions in VRDN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 19, 26 | Tousignant Jennifer | other | 10,000 |
| Aug 19, 26 | Tousignant Jennifer | other | 10,000 |
| Aug 19, 26 | Tousignant Jennifer | sell | 10,000 |
| Aug 14, 26 | Tripuraneni Radhika | other | 40,000 |
| Aug 14, 26 | Tripuraneni Radhika | other | 40,000 |
| Jul 1, 26 | CAIN CHRISTOPHER W. | other | 32,341 |
| Jul 1, 26 | Ajer Jeffrey Robert | other | 32,341 |
| Jul 1, 26 | Moses Jennifer K. | other | 32,341 |
| Jul 1, 26 | Gheuens Sarah | other | 32,341 |
| Jul 1, 26 | Kiselak Tomas | other | 32,341 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VRDN coverage
Recent articles, reports, and earnings notes.
No research on VRDN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VRDN report →Viridian Therapeutics initiated at 'buy' by Bank of America with $47 price target
proactiveinvestors.com · Nov 19
Viridian Therapeutics, Inc. (VRDN) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans Transcript
seekingalpha.com · Nov 9
Viridian Therapeutics Stock Rallies on Positive VRDN-008 Trial Results, Eyes 8-Week Dosing
benzinga.com · Nov 9
Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing
businesswire.com · Nov 9
Viridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
businesswire.com · Nov 6
Wall Street Analysts Predict a 39.68% Upside in Viridian Therapeutics (VRDN): Here's What You Should Know
zacks.com · Nov 6
Viridian Therapeutics: Strong Start For Lumvoa, VRDN-008 Data Ahead
seekingalpha.com · Nov 5
What Viridian Therapeutics (VRDN) Said on Its Q3 Earnings Call
marketbeat.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.